Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Market Cap & Net Worth: Lumosa Therapeutics Co. Ltd. (6535)
Lumosa Therapeutics Co. Ltd. (TWO:6535) has a market capitalization of $768.83 Million (NT$25.44 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11356 globally and #318 in its home market, demonstrating a -6.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lumosa Therapeutics Co. Ltd.'s stock price NT$151.00 by its total outstanding shares 168461825 (168.46 Million).
Lumosa Therapeutics Co. Ltd. Market Cap History: 2015 to 2026
Lumosa Therapeutics Co. Ltd.'s market capitalization history from 2015 to 2026. Data shows growth from $427.64 Million to $768.83 Million (13.36% CAGR).
Lumosa Therapeutics Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lumosa Therapeutics Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
27.64x
Lumosa Therapeutics Co. Ltd.'s market cap is 27.64 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $175.15 Million | $172.04 Million | -$240.94 Million | 1.02x | N/A |
| 2020 | $179.48 Million | $21.65 Million | -$322.56 Million | 8.29x | N/A |
| 2021 | $204.94 Million | $17.36 Million | $95.95 Million | 11.80x | 2.14x |
| 2022 | $200.61 Million | $26.64 Million | -$494.66 Million | 7.53x | N/A |
| 2023 | $347.76 Million | $56.92 Million | -$238.04 Million | 6.11x | N/A |
| 2024 | $1.27 Billion | $39.15 Million | -$424.78 Million | 32.51x | N/A |
| 2025 | $990.32 Million | $35.83 Million | -$340.54 Million | 27.64x | N/A |
Competitor Companies of 6535 by Market Capitalization
Companies near Lumosa Therapeutics Co. Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Lumosa Therapeutics Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lumosa Therapeutics Co. Ltd. Historical Marketcap From 2015 to 2026
Between 2015 and today, Lumosa Therapeutics Co. Ltd.'s market cap moved from $427.64 Million to $ 768.83 Million, with a yearly change of 13.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$768.83 Million | -22.37% |
| 2025 | NT$990.32 Million | -22.20% |
| 2024 | NT$1.27 Billion | +266.03% |
| 2023 | NT$347.76 Million | +73.35% |
| 2022 | NT$200.61 Million | -2.11% |
| 2021 | NT$204.94 Million | +14.18% |
| 2020 | NT$179.48 Million | +2.47% |
| 2019 | NT$175.15 Million | +12.97% |
| 2018 | NT$155.04 Million | +3.22% |
| 2017 | NT$150.20 Million | -33.33% |
| 2016 | NT$225.30 Million | -47.32% |
| 2015 | NT$427.64 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lumosa Therapeutics Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $768.83 Million USD |
| MoneyControl | $768.83 Million USD |
| MarketWatch | $768.83 Million USD |
| marketcap.company | $768.83 Million USD |
| Reuters | $768.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.